AnPac Bio Began Generating Contract Medical Device R&D Revenue
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced a contract with Advanced Life Therapeutics for contract R&D on cancer treatment devices, where AnPac holds a 40% equity interest. Revenue generation is expected to begin in Q3 2021. The company is also engaging in discussions with major medical corporations to enhance its Cancer Differentiation Analysis (CDA) test revenues and to develop new medical devices leveraging its expertise in integrated circuits. CEO Dr. Chris Yu expressed optimism about these developments as potential new revenue streams.
- Entered a multi-year contract R&D project with Advanced Life Therapeutics, potentially starting revenue in Q3 2021.
- Engaged in advanced partnerships with major corporations aimed at increasing CDA test revenue and expanding product pipeline.
- None.
Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations
PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd. (“Advanced Life Therapeutics”), in which the Company holds a minority equity interest of
The Company is also in later stages of partnership/cooperation discussions with a number of major corporations in the medical industry, in order to (a) increase the Company’s commercial Cancer Differentiation Analysis (CDA)-based cancer test revenue, and (b) broaden the Company’s new product pipeline in which the Company and its partner(s) will jointly develop medical devices which will leverage AnPac Bio’s strong expertise in integrated circuit (IC) based core components in medical devices.
Anpac Bio’s CEO, Dr. Chris Yu remarked of this progress, “We are pleased to initiate our first contract medical device R&D to bring additional revenue streams to our company. We also look forward to finalizing the pending major partnerships/cooperation to increase our core cancer screening and detection test revenue, and broaden our product pipeline.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com.
For investor and media inquiries, please contact:
Company:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: phil_case@AnPacbio.com
Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FAQ
What recent partnership has AnPac Bio formed?
When does AnPac Bio expect to start generating revenue from its new partnership?
What is AnPac Bio's focus in its business operations?
What is the significance of AnPac Bio's 40% equity interest in Advanced Life Therapeutics?
What technology does AnPac Bio leverage in its medical devices?
